Potential Biomarkers for Defining the Severity, Progression, and Survival from COVID‑19

Chidiebere Emmanuel Okechukwu

Abstract


Dear Editor, There are potential laboratory biomarkers that can be used to ascertain the severity and progression of coronavirus disease 2019 (COVID‑19), thereby predicting the survival of COVID‑19 patients. For instance, there were rises in the levels of C‑reactive protein (CRP), serum amyloid A, interleukin‑6 (IL‑6), lactate dehydrogenase, neutrophil‑to‑lymphocyte ratio, D‑dimer, cardiac troponin, and renal biomarkers (Urea and creatinine levels;) in COVID‑19 patients, and monitoring these biomarkers is important in defining the severity and progression of COVID‑19 among these patients.

Keywords


COVID‑19; C‑reactive protein; Severity

Full Text:

PDF

References


Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of

biomarkers in diagnosis of COVID‑19‑A systematic review. Life

Sci 2020;254:117788.

Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, et al. Plasma

IP‑10 and MCP‑3 levels are highly associated with disease

severity and predict the progression of COVID‑19. J Allergy

Clin Immunol 2020;146:119‑127.e4.

Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G.

Hematologic, biochemical and immune biomarker abnormalities

associated with severe illness and mortality in coronavirus

disease 2019 (COVID‑19): A meta‑analysis. Clin Chem Lab Med

;58:1021‑8.

Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers

associated with COVID‑19 disease progression. Crit Rev Clin

Lab Sci 2020;57:389‑99.